Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Investigation of COVID-19 Jab Disposals Not on the Table at This Time: Health Minister
May 20, 2022
- LDP Pharma Study Group to Push Price Maintenance for Patented Meds, Rethink of “Off-Year” Re-Pricing towards Honebuto
May 20, 2022
- LDP Social Security Execs Leery of Macroeconomic Indexing
May 20, 2022
- Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Cabometyx Likely to Escape CEA Scheme Unscathed with No Price Cut
May 19, 2022
- 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
- Impact of Annual Price Revisions on Pharma Industry Hard to Gauge Comprehensively: Govt
May 19, 2022
- Cabinet Adopts Ordinance for Emergency Approval, COVID Drugs Subject to New System
May 18, 2022
- 2022 Honebuto Outline Calls for “Planned Investment” Towards a New Capitalism
May 18, 2022
- Dupixent Faces Second Re-Pricing in August with 11.7% Cut
May 18, 2022
- Taiho’s GIST Med Pimitespib, Cabotegravir/Rilpivirine Combo Use Up for PAFSC Review on May 30
May 18, 2022
- MHLW Panels Again Find No Significant Concerns over Safety of COVID-19 Vaccines
May 17, 2022
- Janssen’s COVID-19 Vaccine Up for MHLW Panel Review on May 30
May 17, 2022
- MHLW Orders Label Revisions for Dexamethasone, Betamethasone to Warn of Phaeochromocytoma Crisis
May 16, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
- MHLW Panel Clears Solasia’s PTCL Drug for Approval
May 13, 2022
- Japan Confirms 1st Cases of BA.4, BA.5 Omicron Subvariants
May 13, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…